Bladder Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
In March 2025, Merck Sharp & Dohme LLC announced a study are to learn if people who receive V940 and pembrolizumab are alive ...
US FDA approves GSK's urinary tract infection drug
The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in ...
New Atlas15h
Smarter drug delivery system stores doses under your skin as crystals
For many people, injection needles can be scary – and the larger ones for specialized longer-term medications are far more ...
Fierce Biotech21h
Drug development cost pharma $2.2B per asset in 2024 as GLP-1s drive financial return: Deloitte
The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...
StockStory.org on MSN4d
Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, ...
Pharmabiz17d
Imports of bulk drugs and drug intermediates grow 2.3% in nine months of FY25
The import of bulk drugs and drug intermediates to the country has seen a growth of 2.34 per cent in the first nine months of the current fiscal year, as compared to the same period of last year. The ...
Vanguard18d
NAFDAC arrests 40 suspects, destroys banned drugs, other products worth N100b in Oyo
National Agency for Foods, Drugs Administration and Control, (NAFDAC) has arrested over 40 suspects and destroyed banned pharmaceutical and other products worth N100 billion. This was disclosed by ...
Canada18d
Drug shortages in Canada: Regulations and guidance
Compliance and enforcement actions related to these provisions are undertaken as per Health Canada's Compliance and enforcement policy for health products (POL-0001). The regulatory provisions for ...
ascopubs.org20d
Accelerating Myeloma Drug Development: Will Minimal Residual Disease Replace Progression-Free Survival as an Intermediate Surrogate End Point?
Accelerating Myeloma Drug Development: Will Minimal Residual Disease Replace Progression-Free Survival as an Intermediate Surrogate End Point? The following represents disclosure information provided ...
ascopubs.org20d
Accelerating Myeloma Drug Development: Will Minimal Residual Disease Replace Progression-Free Survival as an Intermediate Surrogate End Point?
However, in our opinion, the most impactful contribution of this collaborative effort is the demonstration and approval of MRD-CR as an intermediate end point to support accelerated drug approvals in ...
Seeking Alpha21d
Generic drugmakers could see negative impact from higher Chinese tariffs
Generic drugmakers could be significantly impacted by President Trump's decision to double the tariff on Chinese goods to 20% as a portion of active pharmaceutical ingredients (APIs) used in ...
C&EN24d
Stereoanalysis of the Antiparasitic Natural Product Callunene and Its Synthetic Intermediates
Department of Organic Chemistry, Faculty of Chemical Technology, University of Chemistry and Technology Prague, Technická 5, Prague 6 16628, Czech Republic Laboratory of Nuclear Magnetic Resonance ...